sunitinib su11248  (MedChemExpress)

Journal: Communications Biology

Article Title: TGFBI promotes liver fibrosis through remodeling the profibrotic microenvironment by a positive feedback regulatory loop

doi: 10.1038/s42003-026-09601-2

Figure Lengend Snippet: A Western blot analyses of PDGF-B in BMDM or RAW264.7 treated with rTGFBI (ng/mL) with the indicated concentrations ( n = 3 independent experiments). B RT-qPCR analyses of PDGF-B in BMDM or RAW264.7 treated with rTGFBI (ng/mL) with the indicated concentrations ( n = 3 independent experiments). C Western blot analysis of the indicated proteins in BMDM or RAW264.7 treated with or without rTGFBI (200 ng/mL) for 6 h. D RT-qPCR analysis of Pdgfb in BMDM or RAW264.7 treated with rTGFBI (200 ng/mL) alone or in combination with integrin αvβ3 or αvβ5 neutralizing antibody ( n = 3 independent experiments). E Flow cytometry analysis and statistical analysis of the percentage of Trem2 + CD9 + subpopulation in BMDM or RAW264.7 transfected with the indicated siRNAs for 24 h and treated with or without rTGFBI (200 ng/mL) for 24 h ( n = 3 independent experiments). F RT-qPCR and Western blot analysis of α-SMA in HSCs cocultured with BMDMs transfected the indicated siRNAs for 24 h and treated with or without rTGFBI (200 ng/mL) for 24 h ( n = 3 independent experiments). G RT-qPCR and Western blot analyses of α-SMA in HSCs treated with rTGFBI or in combination with SU11248 ( n = 3 independent experiments). Mice samples ( n = 4–6 per group). Data were presented as the mean ± SDs; scale bars, 50 µm; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns not significant (Student’s t test).

Article Snippet: SU11248 (PDGFR inhibitor, sunitinib, #HY-10255A, MedChemExpress) and Imatinib Mesylate (PDGFR inhibitor, #HY-50946, MedChemExpress) .

Techniques: Western Blot, Quantitative RT-PCR, Flow Cytometry, Transfection

Journal: International Journal of Molecular Sciences

Article Title: A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

doi: 10.3390/ijms26052192

Figure Lengend Snippet: Targeted inhibition pathways of VEGFR, PDGFR, FGFR, cMET and TIE-2 receptors by multi-kinase inhibitors. The blockade of VEGFR, PDGFR, FGFR, cMET and TIE-2 receptors and their signaling pathways by multi-kinase inhibitors leads to inhibition of glioma vascular permeability, migration, proliferation and survival within angiogenesis. The main FDA-approved multi-target angiogenesis drugs are axitinib, sorafenib, lenvatinib, pazopanib, sunitinib, cabozantinib, nintedanib, regorafenib, aflibercept and ramucirumab. Sharp arrows (→) illustrate stimulation while blunt arrows (┴) indicate inhibition.

Article Snippet: Sunitinib (Sutent ® or SU11248, Pfizer Inc, New York, NY, USA) is also known as INN-sunitinib malate.

Techniques: Inhibition, Protein-Protein interactions, Permeability, Migration

Journal: International Journal of Molecular Sciences

Article Title: A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

doi: 10.3390/ijms26052192

Figure Lengend Snippet: Main in vitro and in vivo studies that demonstrate the efficacy of anti-angiogenic multi-target therapies on brain tumors.

Article Snippet: Sunitinib (Sutent ® or SU11248, Pfizer Inc, New York, NY, USA) is also known as INN-sunitinib malate.

Techniques: In Vitro, In Vivo, Activity Assay, Phospho-proteomics, Activation Assay, Irradiation, Inhibition, Migration

Journal: International Journal of Molecular Sciences

Article Title: A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

doi: 10.3390/ijms26052192

Figure Lengend Snippet: Sunitinib chemical structure. The design was created with ACD/ChemSketch 2.0 (Freeware).

Article Snippet: Sunitinib (Sutent ® or SU11248, Pfizer Inc, New York, NY, USA) is also known as INN-sunitinib malate.

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy

doi: 10.3390/ijms26052192

Figure Lengend Snippet: Main clinical studies that used anti-angiogenic multi-targeted therapy for glioma treatment.

Article Snippet: Sunitinib (Sutent ® or SU11248, Pfizer Inc, New York, NY, USA) is also known as INN-sunitinib malate.

Techniques: Protein-Protein interactions, Drug discovery, Infection, Control, Concentration Assay, Clinical Proteomics, Reflux, Adjuvant